Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P10745
UPID:
RET3_HUMAN
Alternative names:
Interphotoreceptor retinoid-binding protein; Interstitial retinol-binding protein
Alternative UPACC:
P10745; Q0QD34; Q5VSR0; Q8IXN0
Background:
Retinol-binding protein 3, also known as Interphotoreceptor retinoid-binding protein or Interstitial retinol-binding protein, plays a crucial role in the visual cycle. It is responsible for the transport of 11-cis and all-trans retinoids between the retinol isomerase in the pigment epithelium and the visual pigments in the photoreceptor cells of the retina, facilitating the conversion of light into visual signals.
Therapeutic significance:
Retinol-binding protein 3 is directly associated with Retinitis pigmentosa 66, a retinal dystrophy characterized by loss of vision and pigment deposits in the retina. Understanding the role of this protein could lead to novel therapeutic strategies for treating this debilitating disease.